Virus Diseases
Conditions
Brief summary
The SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and how it might effect the working of the Immune system. The aim of the study is therefore to monitor the onset of autoimmune diseases in a large observational study consisting of German health insurance data.
Detailed description
SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand how the virus might effect the working of the Immune system a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID-19. The basic question concerns the burden of the Post-COVID condition. The study investigate which autoimmune diseases or groups of autoimmune diseases are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in subgroups of the population.
Interventions
The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
Sponsors
InGef - Institut für angewandte Gesundheitsforschung Berlin GmbH
BARMER Institut für Gesundheitssystemforschung (bifg)
Techniker Krankenkasse
DAK Gesundheit
AOK PLUS
IKK Classic
Technische Universität Dresden
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* At least one outpatient or inpatient diagnosis of COVID-19 with laboratory detection of the virus (ICD-10: U07.1!) in the year 2020 * Continuously insured with the respective health insurance between 2019-01-01/birth and 2021-06-30/death
Exclusion criteria
* Only an outpatient or inpatient diagnosis of COVID-19 without laboratory detection of the virus( ICD-10:U07.2!) till 30th of June 2021 * At least one outpatient or inpatient diagnosis of COVID-19 with laboratory detection of the virus (ICD-10: U07.1!) in the first half of the year 2021
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Polymyalgia rheumatica | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Polymyalgia rheumatica recorded in outpatient or inpatient setting |
| Incidence of Polymyositis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Polymyositis recorded in outpatient or inpatient setting |
| Incidence of Psoriasis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Psoriasis recorded in outpatient or inpatient setting |
| Incidence of Idiopathic thrombocytopenic purpura | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Idiopathic thrombocytopenic purpura recorded in outpatient or inpatient setting |
| Incidence of rheumatoid arthritis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of rheumatoid arthritis recorded in outpatient or inpatient setting |
| Incidence of Sarcoidosis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Sarcoidosis recorded in outpatient or inpatient setting |
| Incidence of Addison's disease | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Addison's disease recorded in outpatient or inpatient setting |
| Incidence of Alopecia areata | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Alopecia areata recorded in outpatient or inpatient setting |
| Incidence of Autoimmune hemolytic anemia | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Autoimmune hemolytic anemia recorded in outpatient or inpatient setting |
| Incidence of Arteriitis temporalis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Arteriitis temporalis recorded in outpatient or inpatient setting |
| Incidence of Graves' disease | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Graves' disease recorded in outpatient or inpatient setting |
| Incidence of ankylosing spondylitis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of ankylosing spondylitis recorded in outpatient or inpatient setting |
| Incidence of Behcet's disease | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Behcet's disease recorded in outpatient or inpatient setting |
| Incidence of Churg-Strauss disease | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Churg-Strauss disease recorded in outpatient or inpatient setting |
| Incidence of Morbus Crohn | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Morbus Crohn recorded in outpatient or inpatient setting |
| Incidence of Dermatomyositis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Dermatomyositis recorded in outpatient or inpatient setting |
| Incidence of Diabetes type I | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Diabetes type I recorded in outpatient or inpatient setting |
| Incidence of Dermatitis herpetiformis (Duhring's disease) | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Dermatitis herpetiformis (Duhring's disease) recorded in outpatient or inpatient setting |
| Incidence of atopic dermatitis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of atopic dermatitis recorded in outpatient or inpatient setting |
| Incidence of Guillain-Barré-syndrome | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Guillain-Barré-syndrome recorded in inpatient setting |
| Incidence of Goodpasture syndrome | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Goodpasture syndrome recorded in outpatient or inpatient setting |
| Incidence of Hashimoto's thyroiditis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Hashimoto's thyroiditis recorded in outpatient or inpatient setting |
| Incidence of Autoimmune Hepatitis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Autoimmune Hepatitis recorded in outpatient or inpatient setting |
| Incidence of Juvenile rheumatoid arthritis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Juvenile rheumatoid arthritis recorded in outpatient or inpatient setting |
| Incidence of Kawasaki syndrome | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Kawasaki syndrome recorded in outpatient or inpatient setting |
| Incidence of Cutaneous lupus erythematosus | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Cutaneous lupus erythematosus recorded in outpatient or inpatient setting |
| Incidence of Cryoglobulinemia | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Cryoglobulinemia recorded in outpatient or inpatient setting |
| Incidence of Systemic lupus erythematosus | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Systemic lupus erythematosus recorded in outpatient or inpatient setting |
| Incidence of Morphea | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Morphea recorded in outpatient or inpatient setting |
| Incidence of Multiple sclerosis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Multiple sclerosis recorded in outpatient or inpatient setting |
| Incidence of Myasthenia gravis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Myasthenia gravis recorded in outpatient or inpatient setting |
| Incidence of Necrotizing vasculopathy | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Necrotizing vasculopathy recorded in outpatient or inpatient setting |
| Incidence of Bullous pemphigoid | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Bullous pemphigoid recorded in outpatient or inpatient setting |
| Incidence of Pemphigus vulgaris | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Pemphigus vulgaris recorded in outpatient or inpatient setting |
| Incidence of Polyarteritis nodosa | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Polyarteritis nodosa recorded in outpatient or inpatient setting |
| Incidence of Sjögren's syndrome | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Sjögren's syndrome recorded in outpatient or inpatient setting |
| Incidence of Takayasu arteritis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Takayasu arteritis recorded in outpatient or inpatient setting |
| Incidence of Ulcerative colitis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Ulcerative colitis recorded in outpatient or inpatient setting |
| Incidence of Vitiligo | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Vitiligo recorded in outpatient or inpatient setting |
| Incidence of Wegener's disease | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of Wegener's disease recorded in outpatient or inpatient setting |
| Incidence of primary biliary cholangitis | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of primary biliary cholangitis recorded in outpatient or inpatient setting |
| Incidence of celiac disease | At least 12 weeks after the infection by SARS-CoV-2 | Incidence of a diagnosis of celiac disease recorded in outpatient or inpatient setting |
Countries
Germany
Outcome results
None listed